Wet Macular Degeneration Clinical Trials 2024

Wet Macular Degeneration Clinical Trials 2024

Wet Macular Degeneration research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in wet macular degeneration clinical trials today.

Trials for Age-Related Macular Degeneration Patients

Trials for AMD Patients

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to wet macular degeneration

What are the top hospitals conducting wet macular degeneration research?

In the battle against wet macular degeneration, several top hospitals are spearheading innovative clinical trials to combat this progressive eye condition. Located in Reno, Sierra Eye Associates is at the forefront with five active trials and a total of 12 studies dedicated to wet macular degeneration. Their commitment began in 2018 when they recorded their first trial, aiming to improve treatments for this complex disease. Retina Consultants of Texas, based in The Woodlands, is also actively engaged in finding new solutions with four ongoing trials and a history of eight conducted studies since joining the fight against wet macular degeneration in 2018.

Meanwhile, Boston's Ophthalmic Consultants of Boston has been contributing significantly with three active clinical trials and a noteworthy record of nine previous investigations into this condition since embarking on their research journey back in 2017. Charles Retina Institute located in Germantown shares similar dedication as it currently conducts three ongoing clinical tests while having previously completed six experiments since initiating its pioneering investigation into wet macular degeneration just three years ago.

Even Santa Barbara plays an important role through its local location where two active clinical trials aimed at combating wet macular degeneration are underway; although relatively newer players compared to others on our list having only begun their research efforts last year(2019), every contribution counts toward potential breakthroughs that can positively impact countless lives affected by this visually impairing condition.

These leading hospitals demonstrate unwavering commitment to advancing medical knowledge and treatment options for those diagnosed with wet macular degeneration. Together, they represent hope for patients worldwide as they strive towards uncovering effective therapies that bring brighter tomorrows for individuals facing visual challenges caused by this progressive eye disease.

Which are the best cities for wet macular degeneration clinical trials?

When it comes to wet macular degeneration clinical trials, a few cities emerge as leading hubs for research and development. Phoenix, Arizona takes the lead with 13 active trials investigating treatments like ADVM-022, RGX-314, and CLS-AX. Austin, Texas follows closely with 12 ongoing studies focused on innovative approaches such as Faricimab and Aflibercept High Dose VEGF Trap-Eye. In Reno, Nevada and Philadelphia, Pennsylvania, both cities boast 11 active trials exploring promising interventions like RGX-314 and Faricimab. Lastly, Boston in Massachusetts showcases its dedication to finding effective treatments through 10 active trials targeting wet macular degeneration. These cities provide individuals affected by this condition access to cutting-edge clinical research that holds promise for improved outcomes in the future.

Which are the top treatments for wet macular degeneration being explored in clinical trials?

Exciting advancements are being made in the realm of wet macular degeneration, with several top treatments currently under investigation through clinical trials. Among these potential game-changers is bevacizumab, which has caught the attention with its involvement in one active and four all-time trials dedicated to wet macular degeneration since 2018. Another contender making waves is RGX-314, also participating in one ongoing trial and two past trials for this condition since its introduction in 2019. Additionally, faricimab shows promise with one current and three historical wet macular degeneration trials since its debut in 2019. Let's not overlook the newest entrants: RGX-314 Dose 2 and doxycycline hyclate both show potential as they make their mark on the scene by joining a single active trial each for this debilitating eye disease starting from 2020 onwards. These pioneering treatments hold hope for a brighter future for individuals battling wet macular degeneration around the world.

What are the most recent clinical trials for wet macular degeneration?

Recent advancements in clinical trials offer hope for individuals with wet macular degeneration. One of the promising studies is investigating Dose 1, which has progressed to Phase 2 after successful Phase 1 results. Additionally, CLS-AX at a dosage of 1.0 mg is being evaluated in Phase 2 trials as a potential treatment option. Another trial focuses on the efficacy of Ranibizumab for wet macular degeneration and has reached Phase 4 after previous phases showed promise. Furthermore, AIV007 Dose 1 and Part A are undergoing Phase 1 evaluations to assess their effectiveness against this debilitating condition. These ongoing trials bring optimism for improved treatments and outcomes for those affected by wet macular degeneration.

What wet macular degeneration clinical trials were recently completed?

Recent advancements in clinical trials for wet macular degeneration have yielded promising results, offering hope to those affected by this debilitating condition. Notably, Sandoz completed a trial investigating the efficacy of SOK583A1 in May 2022, while a previous trial testing a higher dosage of SOK583A1 (40 mg/mL) wrapped up in May 2021. Additionally, AsclepiX Therapeutics concluded their research on AXT107 0.1 mg in February 2021. These trials signify significant progress and underscore the commitment of various sponsors such as Novartis Pharmaceuticals, Clearside Biomedical, Unity Biotechnology, Samsung Bioepis Co., Ltd., Aerie Pharmaceuticals, and Hoffmann-La Roche to seek innovative solutions against wet macular degeneration.